Compare
Revvity, Inc. vs Bruker Corp vs Agilent Technologies, Inc. vs Pacific Biosciences of California, Inc.
| Latest fiscal year | Revvity, Inc. RVTY | Bruker Corp BRKR | Agilent Technologies, Inc. A | Pacific Biosciences of California, Inc. PACB |
|---|---|---|---|---|
| Year ended | 2025-12-28 | 2025-12-31 | 2025-10-31 | 2025-12-31 |
| Revenue | $2.86B | $3.44B | $6.95B | $160.00M |
| Revenue growth (YoY) | +3.7% | +2.1% | +6.7% | +3.9% |
| Gross margin | n/a | 45.9% | 52.4% (computed) | 28.6% |
| Operating margin | 12.5% | 2.0% | 21.3% | -346.2% |
| Net margin | 8.4% | -0.2% | 18.8% | -341.5% |
| Net income | $241.20M | -$8.30M | $1.30B | -$546.38M |
| EPS (Diluted) | $2.07 | -$0.15 | $4.57 | -$1.82 |
| Operating cash flow | $582.93M | $134.10M | $1.56B | -$111.21M |
| Free cash flow | $509.41M | $43.30M | $1.15B | -$113.92M |
| Cash & equivalents | $919.86M | $298.80M | $1.79B | $63.71M |
| Total assets | $12.17B | $6.24B | $12.73B | $784.08M |
| Total liabilities | $4.92B | $3.73B | $5.99B | $778.73M |
| Shareholders' equity | $7.25B | $2.47B | $6.74B | $5.35M |
| Return on year-end equity | 3.3% | -0.3% | 19.3% | n/m |
| Shares outstanding | 112.28M | 152.14M | 283.05M | 301.96M |
Revenue, most recent five fiscal years
| Fiscal year | Revvity, Inc. | Bruker Corp | Agilent Technologies, Inc. | Pacific Biosciences of California, Inc. |
|---|---|---|---|---|
| Latest | $2.86B Ended 2025-12-28 | $3.44B Ended 2025-12-31 | $6.95B Ended 2025-10-31 | $160.00M Ended 2025-12-31 |
| 1 year earlier | $2.76B Ended 2024-12-29 | $3.37B Ended 2024-12-31 | $6.51B Ended 2024-10-31 | $154.01M Ended 2024-12-31 |
| 2 years earlier | $2.75B Ended 2023-12-31 | $2.96B Ended 2023-12-31 | $6.83B Ended 2023-10-31 | $200.52M Ended 2023-12-31 |
| 3 years earlier | $3.31B Ended 2023-01-01 | $2.53B Ended 2022-12-31 | $6.85B Ended 2022-10-31 | $128.30M Ended 2022-12-31 |
| 4 years earlier | $3.83B Ended 2022-01-02 | $2.42B Ended 2021-12-31 | $6.32B Ended 2021-10-31 | $130.51M Ended 2021-12-31 |